Published in Infect Immun on December 01, 1989
Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun (1994) 1.68
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect Immun (2002) 1.55
Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients. Infect Immun (1991) 1.17
Vaccine-induced intestinal immunity to ricin toxin in the absence of secretory IgA. Vaccine (2010) 0.95
Trypsin-dependent production of an antibacterial substance by a human Peptostreptococcus strain in gnotobiotic rats and in vitro. Appl Environ Microbiol (1993) 0.91
Manganese binds to Clostridium difficile Fbp68 and is essential for fibronectin binding. J Biol Chem (2010) 0.85
Inactivation of tryptic activity by a human-derived strain of Bacteroides distasonis in the large intestines of gnotobiotic rats and mice. Appl Environ Microbiol (1996) 0.81
Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet (1978) 11.99
Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J (1978) 8.47
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16
Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40
Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis (1984) 3.07
Antibiotic-associated pseudomembranous colitis. Rev Infect Dis (1980) 3.02
Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89
Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions. J Clin Microbiol (1982) 2.52
Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol (1985) 2.46
Effects of Clostridium difficile toxin on tissue-cultured cells. J Infect Dis (1980) 2.30
Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01
Modulation of cytotoxin production by Clostridium difficile in the intestinal tracts of gnotobiotic mice inoculated with various human intestinal bacteria. Appl Environ Microbiol (1985) 1.47
Effect of various diets on toxin production by two strains of Clostridium difficile in gnotobiotic mice. Infect Immun (1987) 1.11
Improved enzyme immunoassays for the detection of antigens in fecal specimens. Investigation and correction of interfering factors. J Immunol Methods (1984) 1.10
Improved method for IgG purification from various animal species by ion exchange chromatography. J Immunol Methods (1984) 1.07
Stool desorbing activity: a possible cause of false-positive reactions in competitive enzyme immunoassays. J Clin Microbiol (1985) 1.02
Influence of intestinal microflora on the tryptic activity during lactation in rats. Lab Anim (1986) 0.99
Membrane digestion. A concept of enzyme hydrolysis on cell membranes. Biochim Biophys Acta (1973) 0.96
Emergence in gnotobiotic mice of nontoxinogenic clones of Clostridium difficile from a toxinogenic one. Infect Immun (1988) 0.94
Immunochemical and structural similarities in toxin A and toxin B of Clostridium difficile shown by binding to monoclonal antibodies. Toxicon (1988) 0.93
Relationship between levels of Clostridium difficile toxin A and toxin B and cecal lesions in gnotobiotic mice. Infect Immun (1989) 0.91
Fixation of Clostridium difficile toxin A and cholera toxin to intestinal brush border membranes from axenic and conventional mice. Infect Immun (1989) 0.83
Stimulation of enzyme secretion from isolated pancreatic acini by Clostridium difficile toxin B. Toxicol Lett (1986) 0.79
A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA (1994) 3.66
Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis (1997) 2.53
Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol (1999) 2.40
The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis (2000) 2.06
Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology (1989) 2.03
Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol (1995) 1.98
[Sodium taurocholate, a germination factor for anaerobic bacterial spores "in vitro" and "in vivo" (author's transl)]. Ann Microbiol (Paris) (1975) 1.71
Increase in the population of duodenal immunoglobulin A plasmocytes in axenic mice associated with different living or dead bacterial strains of intestinal origin. Infect Immun (1978) 1.66
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Relative validity and reproducibility of a French dietary history questionnaire. Int J Epidemiol (1997) 1.54
Studies on the aetiology of byssinosis. Br J Ind Med (1971) 1.53
Nutritional requirements for growth and yeastlike development of Mucor rouxii under carbon dioxide. J Bacteriol (1970) 1.38
Implantation of bacteria from the digestive tract of man and various animals into gnotobiotic mice. Am J Clin Nutr (1980) 1.29
Seroepidemiologic, molecular, and phylogenetic analyses of simian T-cell leukemia viruses (STLV-I) from various naturally infected monkey species from central and western Africa. Virology (1994) 1.28
Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients. Infect Immun (1991) 1.17
Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii. Antimicrob Agents Chemother (1984) 1.14
Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting. Clin Ther (2000) 1.10
Diet and the equilibrium between bacteria and yeast implanted in gnotobiotic rats. Am J Clin Nutr (1972) 1.07
The isolation of L(+)-methionine sulphoxide from the blowfly Phormia regina Meigen. Biochem J (1966) 1.07
Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos (1989) 1.05
Mass-spectrometric determination of the amino acid sequences in peptides isolated from the protein silk fibroin of Bombyx mori. Biochem J (1969) 1.04
[Relationship between the development of the intestinal IgA immune system and the establishment of microbial flora in the digestive tract of young holoxenic mice]. Ann Immunol (Paris) (1983) 1.01
Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother (1987) 1.00
Filamentous growth of Mucor rouxii under nitrogen. J Bacteriol (1970) 0.99
Selective enumeration of Bacteroides vulgatus and B. distasonis organisms in the predominant human fecal flora by using monoclonal antibodies. Appl Environ Microbiol (1996) 0.99
Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study. J Gen Microbiol (1990) 0.98
Antinuclear antibodies. Clinical significance of titers and fluorescence patterns. Am J Clin Pathol (1974) 0.96
Relationships between rotavirus diarrhea and intestinal microflora establishment in conventional and gnotobiotic mice. J Clin Microbiol (1986) 0.96
Emergence in gnotobiotic mice of nontoxinogenic clones of Clostridium difficile from a toxinogenic one. Infect Immun (1988) 0.94
Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig Dis Sci (1990) 0.92
Abdominal vagotomy does not block carbohydrate-conditioned flavor preferences in rats. Physiol Behav (1996) 0.92
Relationship between levels of Clostridium difficile toxin A and toxin B and cecal lesions in gnotobiotic mice. Infect Immun (1989) 0.91
Pharmaceutical probiotics for the treatment of anaerobic and other infections. Anaerobe (2006) 0.91
A novel model of a metastatic human breast tumour xenograft line. Br J Cancer (1993) 0.90
Increased flavor acceptance and preference conditioned by the postingestive actions of glucose. Physiol Behav (1998) 0.89
Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res (1993) 0.87
Possible interaction between warfarin and Lycium barbarum L. Ann Pharmacother (2001) 0.86
No effect of apolipoprotein E on neuronal cell death due to excitotoxic and apoptotic agents in vitro and neonatal hypoxic ischaemia in vivo. Eur J Neurosci (2000) 0.85
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia (2007) 0.85
Influence of the intestinal microflora on the elimination of warfarin in the rat. Drug Metab Dispos (1982) 0.85
Ciprofloxacin-associated Clostridium difficile disease. Lancet (1995) 0.84
[Degradation and uptake of 14C labeled casein peptides by mixed bacteria of the rumen]. Reprod Nutr Dev (1998) 0.83
Fixation of Clostridium difficile toxin A and cholera toxin to intestinal brush border membranes from axenic and conventional mice. Infect Immun (1989) 0.83
The importance of taste and palatability in carbohydrate-induced overeating in rats. Am J Physiol (1996) 0.83
Deprivation, palatability and the micro-structure of meals in human subjects. Appetite (1984) 0.82
Devazepide, a CCK(A) antagonist, attenuates the satiating but not the preference conditioning effects of intestinal carbohydrate infusions in rats. Pharmacol Biochem Behav (1998) 0.82
Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats. Pharm Res (1991) 0.82
Glycosylation of hydroxylysine in collagens. Nat New Biol (1971) 0.81
Carbohydrate, fat, and protein condition similar flavor preferences in rats using an oral-delay procedure. Physiol Behav (1995) 0.80
The measurement of food preferences in humans: do taste-and-spit tests predict consumption? Physiol Behav (1987) 0.79
Twenty-four-hour patterns of sleep in depression. Sleep (1991) 0.79
A therapeutic area review of oncology products and players. Expert Opin Emerg Drugs (2001) 0.79
Some biological properties and an in vivo evaluation of tyrosine phenol-lyase on growth of B-16 melanoma. Cancer Res (1976) 0.78
[Effect of orally administered bovine lactoferrin and bovine IgG on the establishment of Escherichia coli in the digestive tract of gnotobiotic mice and human newborn infants]. Ann Microbiol (Paris) (1984) 0.78
Effect of oral Saccharomyces boulardii treatment on the activity of Clostridium difficile toxins in mouse digestive tract. Toxicon (1992) 0.77
Intracellular nitric oxide assessment in whole blood leukocytes by flow cytometry: optimization and applicability to monitor patients with chronic graft nephropathy. J Immunol Methods (2009) 0.77
NADPH diaphorase-containing striatal or cortical neurons are resistant to apoptosis. Neurobiol Dis (1996) 0.77
Role of the intestinal microflora in clonazepam metabolism in the rat. Xenobiotica (1984) 0.76
Sleep polygraphic variables in anorexia nervosa and depression: a comparative study in adolescents. J Affect Disord (1992) 0.76
Evolution of the caecal epithelial barrier during Clostridium difficile infection in the mouse. Gut (1989) 0.76
Comment on 'The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients'. J Infect (1998) 0.75
The effect of broad-spectrum antibiotics on warfarin excretion and metabolism in the rat. Res Commun Chem Pathol Pharmacol (1981) 0.75
[Multiple cutaneous reticulohistiocytosis]. Ann Dermatol Venereol (2000) 0.75
Influence of rotaviral diarrhea on intestinal microflora establishment in conventional and axenic mice. Prog Clin Biol Res (1985) 0.75
Influence of rotaviral diarrhea on some bacterial functions in the intestine of conventional mice. Prog Clin Biol Res (1985) 0.75
A simple technique for the estimation of viral antibody levels by immunofluorescence. Med Lab Technol (1974) 0.75
[The contribution of sulpiride to ketamine anesthesia]. Rev Stomatol Chir Maxillofac (1975) 0.75
Influence of L-tyrosine phenol-lyase on the growth and metabolism of B16 melanoma. Cancer Treat Rep (1979) 0.75
Quality control of blood glucose meters is a must! (Contribution of the hemocue glucose analyser) Diabetes Metab (1998) 0.75
Naps and depression. Acta Psychiatr Belg (1994) 0.75
A methodological strategy to analyze and improve the French rainwater harvesting regulation in relation to quality. Water Sci Technol (2013) 0.75
[Kinetics of setting up of a human fecal flora in germ free mice and trial of decontamination of antibiotherapy (author's transl)]. Ann Microbiol (Paris) (1976) 0.75
Effect of an Escherichia coli strain on intestinal IgA plasmocyte stimulation and serum antibody response in gnotobiotic mice. Prog Clin Biol Res (1985) 0.75
Progression of the renal graft: treatment of acute rejection based on a biopsy against a presumptive diagnosis. Transplant Proc (2005) 0.75
Treatment of acute focal cerebral ischemia with prostacyclin. Stroke (1983) 0.75
Miles to go before we sleep. MH (1975) 0.75
[Pharyngeal paresthesia. Therapeutic considerations, value of using sulpiride]. Sem Hop Ther (1976) 0.75
Combination of biomolecular and stable isotope techniques to determine the origin of organic matter used by bacterial communities: application to sediment. J Microbiol Methods (1999) 0.75
Increased tyrosine phenol-lyase activity in mice following pyridoxal phosphate administration. Cancer Res (1978) 0.75
Does gastrointestinal Candida albicans prevent ubiquinone absorption? Med Hypotheses (2001) 0.75
Effects of ammonia and amino acids on the growth and proteolytic activity of three species of rumen bacteria: Prevotella albensis, Butyrivibrio fibrisolvens, and Streptococcus bovis. Curr Microbiol (2000) 0.75
[Evolution of fecal microflora in a "heteroxenic" infant maintained in a plastic isolator and trial on decontamination by antibiotherapy (author's transl)]. Ann Microbiol (Paris) (1976) 0.75
Modification of focal cerebral ischemia by prostacyclin and indomethacin. J Neurosurg (1983) 0.75
Albumin and alkaline phosphatase as factors involved in the regulation of tyrosine phenol-lyase activity. Res Commun Chem Pathol Pharmacol (1978) 0.75
[The écouages. Medico-legal activity in Picardy under the old regime]. Med Leg Dommage Corpor (1974) 0.75
New rapid determination of pyridoxal phosphate using tyrosine phenol-lyase. J Pharm Sci (1977) 0.75
Biliary excretion of warfarin metabolites and their metabolism by rat gut flora. Life Sci (1977) 0.75
[Present status of Primperan in the surgical milieu]. Sem Hop Ther (1976) 0.75
Human diseases due to food-borne bacterial toxins and toxins produced in the digestive tract. World Rev Nutr Diet (1993) 0.75